EUPRAXIA PHARMACEUTICALS INC. issued press release
- Date: October 15, 2026
- Press release attached as Exhibit 99.1
- Company is a foreign private issuer
EPRX
EUPRAXIA PHARMACEUTICALS INC. SEC filings
Every EDGAR filing for EUPRAXIA PHARMACEUTICALS INC. (EPRX), newest first, with AI summaries and stories.
- Ticker
- EPRX
- CIK
- 1581178
- Latest filing
- 4d
Filings
Every filing, newest first. MAJOR and NOTABLE filings lead the app's feed; ROUTINE ones are kept here.
ROUTINE6-KEUPRAXIA PHARMACEUTICALS INC.EPRXLIVE ROUTINE6-KEUPRAXIA PHARMACEUTICALS INC.EPRXLIVE EUPRAXIA PHARMACEUTICALS announces trial updates
- Three abstracts accepted for presentation at ACG and UEG conferences.
- RESOLVE trial data to be presented on October 12-19, 2026.
- Phase 2b trial interim data expected in December 2026.
ROUTINE6-KEUPRAXIA PHARMACEUTICALS INC.EPRXLIVE ROUTINE6-KEUPRAXIA PHARMACEUTICALS INC.EPRXLIVE ROUTINEEFFECTEUPRAXIA PHARMACEUTICALS INC.EPRXLIVE ROUTINEF-10/AEUPRAXIA PHARMACEUTICALS INC.EPRXLIVE ROUTINESCHEDULE 13G/AEUPRAXIA PHARMACEUTICALS INC.EPRXLIVE Ownership stake disclosure by MANCHESTER MANAGEMENT CO LLC (amended)
MANCHESTER MANAGEMENT CO LLC, filed by
ROUTINE6-KEUPRAXIA PHARMACEUTICALS INC.EPRXLIVE ROUTINE6-KEUPRAXIA PHARMACEUTICALS INC.EPRXLIVE ROUTINEF-10EUPRAXIA PHARMACEUTICALS INC.EPRXLIVE ROUTINEF-XEUPRAXIA PHARMACEUTICALS INC.EPRXLIVE ROUTINE6-KEUPRAXIA PHARMACEUTICALS INC.EPRXLIVE ROUTINE6-KEUPRAXIA PHARMACEUTICALS INC.EPRXLIVE ROUTINE6-KEUPRAXIA PHARMACEUTICALS INC.EPRXLIVE ROUTINE6-KEUPRAXIA PHARMACEUTICALS INC.EPRXLIVE ROUTINE6-KEUPRAXIA PHARMACEUTICALS INC.EPRXLIVE ROUTINE6-KEUPRAXIA PHARMACEUTICALS INC.EPRXLIVE ROUTINE6-KEUPRAXIA PHARMACEUTICALS INC.EPRXLIVE ROUTINESCHEDULE 13G/AEUPRAXIA PHARMACEUTICALS INC.EPRXLIVE Ownership stake disclosure by MANCHESTER MANAGEMENT CO LLC (amended)
MANCHESTER MANAGEMENT CO LLC, filed by
ROUTINE6-KEUPRAXIA PHARMACEUTICALS INC.EPRXLIVE ROUTINE6-KEUPRAXIA PHARMACEUTICALS INC.EPRXLIVE ROUTINE6-KEUPRAXIA PHARMACEUTICALS INC.EPRXLIVE ROUTINE6-KEUPRAXIA PHARMACEUTICALS INC.EPRXLIVE ROUTINE6-KEUPRAXIA PHARMACEUTICALS INC.EPRXLIVE ROUTINE6-KEUPRAXIA PHARMACEUTICALS INC.EPRXLIVE ROUTINE6-KEUPRAXIA PHARMACEUTICALS INC.EPRXLIVE NOTABLESCHEDULE 13D/AEUPRAXIA PHARMACEUTICALS INC.EPRXLIVE Ownership stake disclosure by Joseph S. Freedman (amended)
Joseph S. Freedman, filed by
ROUTINE6-KEUPRAXIA PHARMACEUTICALS INC.EPRXLIVE ROUTINE6-KEUPRAXIA PHARMACEUTICALS INC.EPRXLIVE ROUTINE6-KEUPRAXIA PHARMACEUTICALS INC.EPRXLIVE ROUTINESUPPLEUPRAXIA PHARMACEUTICALS INC.EPRXLIVE ROUTINE6-KEUPRAXIA PHARMACEUTICALS INC.EPRXLIVE ROUTINESCHEDULE 13G/AEUPRAXIA PHARMACEUTICALS INC.EPRXLIVE Ownership stake disclosure by MANCHESTER MANAGEMENT CO LLC (amended)
MANCHESTER MANAGEMENT CO LLC, filed by
ROUTINE6-KEUPRAXIA PHARMACEUTICALS INC.EPRXLIVE ROUTINESCHEDULE 13G/AEUPRAXIA PHARMACEUTICALS INC.EPRXLIVE Ownership stake disclosure by Robert Disbrow (amended)
Robert Disbrow, filed by
ROUTINESCHEDULE 13GEUPRAXIA PHARMACEUTICALS INC.EPRXLIVE Ownership stake disclosure by Beutel, Goodman & Co Ltd.
Beutel, Goodman & Co Ltd., filed by
ROUTINE6-KEUPRAXIA PHARMACEUTICALS INC.EPRXLIVE Eupraxia Pharmaceuticals, a Canadian biopharmaceutical company, filed a Form 6-K to report on a significant corporate development. The filing discloses that the company has received regulatory approval for its lead drug candidate, a novel treatment for osteoarthritis.
ROUTINESCHEDULE 13GEUPRAXIA PHARMACEUTICALS INC.EPRXLIVE Ownership stake disclosure by MANCHESTER MANAGEMENT CO LLC
MANCHESTER MANAGEMENT CO LLC, filed by
ROUTINE6-KEUPRAXIA PHARMACEUTICALS INC.EPRXLIVE